May 27 2011
The Economist profiles Plasmodium vivax, a type of malaria that affects between 80 million to 390 million people worldwide annually with a cost to sufferers between $1.4 billion and $4 billion each year. However, compared with the related Plasmodium falciparum parasite, vivax rarely kills and therefore falls lower on the list of global health funding priorities, according to the magazine, which also presents a video titled, "Malaria's frontlines" (5/26).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. |